Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 5/20 | 0.33 |
| ▸ | CDK1 | P06493 | 5/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22070046 | 0.95 | — | — | |
| SCHEMBL21670412 | 0.78 | JAK1 (0.39) | AURKA | |
| SCHEMBL29479926 | 0.78 | JAK1 (0.39) | AURKA | |
| SCHEMBL29479912 | 0.76 | HCAR1 (0.37) | AURKA | |
| SCHEMBL21670404 | 0.76 | HCAR1 (0.37) | AURKA | |
| SCHEMBL22070043 | 0.74 | — | — | |
| SCHEMBL22070053 | 0.74 | HTR2A (0.34) | — | |
| SCHEMBL21670390 | 0.72 | JAK1 (0.34) | AURKA | |
| SCHEMBL29479916 | 0.72 | JAK1 (0.34) | AURKA | |
| SCHEMBL4833110 | 0.68 | CCND1 (0.54) | CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993604-B2 | Substituted pyrazolo[4,3-H]quinazolines as protein kinase inhibitors | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2024-05-28 | — | — | US | disclosed |
| US-20220227775-A1 | 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2022-07-21 | — | — | US | disclosed |
| CN-111094291-B | 1H-pyrazolo [4,3-H ] quinazoline compound as protein kinase inhibitor | 晟科药业（江苏）有限公司 | 2022-06-21 | — | — | CN | disclosed |
| EP-3666774-B1 | 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR | SHENGKE PHARMACEUTICALS JIANGSU LTD (CN) | 2022-05-11 | — | — | EP | disclosed |
| EP-3666774-B1 | 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR | SHENGKE PHARMACEUTICALS JIANGSU LTD (CN) | 2022-05-11 | — | — | EP | disclosed |
| US-11319323-B2 | Substituted pyrazolo[4,3-H]quinazolines as protein kinase inhibitors | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-11319323-B2 | Substituted pyrazolo[4,3-H]quinazolines as protein kinase inhibitors | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-20210147424-A1 | 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2021-05-20 | — | — | US | disclosed |
| US-20210147424-A1 | 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2021-05-20 | — | — | US | disclosed |
| EP-3666774-A1 | 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR | Shengke Pharmaceuticals (Jiangsu) Ltd. (CN) | 2020-06-17 | — | — | EP | disclosed |
| EP-3666774-A1 | 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR | Shengke Pharmaceuticals (Jiangsu) Ltd. (CN) | 2020-06-17 | — | — | EP | disclosed |
| CN-111094291-A | 1H-pyrazolo [4,3-H ] quinazoline compound as protein kinase inhibitor | 晟科药业（江苏）有限公司 | 2020-05-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11993604-B2 | Substituted pyrazolo[4,3-H]quinazolines as protein kinase inhibitors | CDK1, CDK2, CDK3 | EZH2 2473/4885AURKA 111/4885CDK1 1/4885 |
| US-20220227775-A1 | 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR | CDK1, CDKL1, CDK2 | EZH2 1984/4885AURKA 121/4885CDK1 1/4885 |
| US-20210147424-A1 | 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR | CDK1, CDKL1, CDK2 | EZH2 1984/4885AURKA 121/4885CDK1 1/4885 |
| US-11319323-B2 | Substituted pyrazolo[4,3-H]quinazolines as protein kinase inhibitors | CDK1, CDK2, CDK3 | EZH2 2473/4885AURKA 111/4885CDK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.